A phase I study of AIT-082 in healthy elderly volunteers

被引:0
|
作者
Michael Grundman
Martin Farlow
Guerry Peavy
Hyun T. Kim
Edmund Capparelli
Arlan N. Schultz
David P. Salmon
Steven H. Ferris
Richard Mohs
Ronald G. Thomas
Kimberly Schafer
Karen Campbell
Ann Marie Hake
Barbara Schoos
Leon J. Thal
机构
[1] Pediatrics University of California,Department of Neurology
[2] Indiana University School of Medicine,Department of Psychiatry
[3] New York University School of Medicine,Department of Psychiatry
[4] Mount Sinai School of Medicine Bronx,Department of Neurosciences
[5] University of California,undefined
[6] San Diego,undefined
来源
Journal of Molecular Neuroscience | 2002年 / 18卷
关键词
AIT-082; neotrofin; phase I; clinical trial; pharmacokinetics;
D O I
暂无
中图分类号
学科分类号
摘要
A Phase I, double-blind, placebo-controlled, single-dose, escalation study of the purine derivative, AIT-082 (Neotrofin™, NeoTherapeutics, Inc.) was conducted in healthy elderly volunteers. This trial was designed to evaluate single-dose safety, tolerability, and pharmacokinetics. Potential cognitive domains that might benefit from AIT-082 were preliminarily investigated. AIT-082 is currently being developed as a potential treatment for Alzheimer’s disease (AD). Preclinical studies indicate that AIT-082 has memory-enhancing properties, stimulates neuritogenesis, and upregulates neurotrophic factors. Subjects received a single oral dose of AIT-082 or placebo on a weekly basis for 5 wk. All patients received a placebo dose at baseline. Six subjects received increasing doses of AIT-082 over the next 4 wk at doses of 0.6, 2.0, 6.0, and 20.0 mg of AIT-082 per kilogram of body weight. Two subjects received placebo throughout the trial. Nine subjects were recruited. One subject was withdrawn after the third treatment visit owing to poor venous access. There were no serious adverse events. The drug was well-tolerated. The time to peak drug concentration was approx 85 min with an elimination half-life of approx 17.6 h. Performance on the Number Comparison, Symbol Digit, and Trails A tests improved with AIT-082 dosing compared to baseline (placebo). In conclusion, AIT-082 was rapidly absorbed by the oral route with a half-life suitable for once daily dosing. No problems with tolerability or safety were demonstrated.
引用
收藏
页码:283 / 293
页数:10
相关论文
共 50 条
  • [1] A phase I study of AIT-082 in healthy elderly volunteers
    Grundman, M
    Farlow, M
    Peavy, G
    Kim, HT
    Capparelli, E
    Schultz, AN
    Salmon, DP
    Ferris, SH
    Mohs, R
    Thomas, RG
    Schafer, K
    Campbell, K
    Hake, AM
    Schoos, B
    Thal, LJ
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2002, 18 (03) : 283 - 293
  • [2] AIT-082, a unique purine derivative with neuroregenerative properties
    Glasky, AJ
    Ritzmann, RF
    Rathbone, MP
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) : R49 - R49
  • [4] NeoTherapeutics begins US clinical trials AIT-082
    不详
    DRUG NEWS & PERSPECTIVES, 1997, 10 (06) : 353 - 353
  • [5] Electrophysiological studies and binding analysis of AIT-082, a cognitive agent
    Peng, L
    Huang, R
    Pfadenhauer, E
    Glasky, MS
    Glasky, AJ
    JOURNAL OF NEUROCHEMISTRY, 2000, 74 : S37 - S37
  • [6] THE INTERACTION OF ETHANOL WITH THE COGNITIVE ENHANCERS TACRINE, PHYSOSTIGMINE, AND AIT-082
    RITZMANN, RF
    GLASKY, A
    STEINBERG, A
    MELCHIOR, CL
    JOURNALS OF GERONTOLOGY, 1994, 49 (02): : B51 - B53
  • [7] Effect of a memory-enhancing drug, AIT-082, on the level of synaptophysin
    Lahiri, DK
    Ge, YW
    Farlow, MR
    VASCULAR FACTORS IN ALZHEIMER'S DISEASE, 2000, 903 : 387 - 393
  • [8] Increased level of synaptophysin with the treatment of memory enhancing drug AIT-082
    Lahiri, DK
    Ge, YW
    Farlow, MR
    NEUROLOGY, 1999, 52 (06) : A480 - A481
  • [9] The neurocogitive effects of AIT-082 (neotrofin) in patients with Alzheimer's disease
    Fleming, K
    Carreon, D
    Alva, G
    Polkin, S
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S86 - S86
  • [10] Effects of AIT-082, a purine derivative, on tremor induced by arecoline or oxotremorine in mice
    Gao Nannan
    Yang Runmei
    Lin Fusheng
    Zhang Shoulan
    Lei Guangqing
    PHARMACOLOGY, 2007, 80 (01) : 21 - 26